newsfilter
← Latest News
Business Wire·

Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 1

  • Compass Pathways plc (Nasdaq: CMPS) announced management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026.
  • The company will participate in a fireside chat scheduled for 3:25pm ET.
  • A live audio webcast of the event will be available at the provided SummitCast link.
  • A replay of the webcast will be accessible for 30 days on the Investors section of the Compass website.
  • Compass is developing COMP360 psilocybin, an investigational treatment for treatment-resistant depression (TRD) & post-traumatic stress disorder (PTSD).
  • COMP360 holds Breakthrough Therapy designation from the U.S. FDA for TRD.
  • The treatment has Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD.
  • The company is executing a late-stage trial evaluating COMP360 for PTSD.
  • Compass is headquartered in London, UK, with a U.S. office in New Jersey.
Keywords
Biotechnology,Health,Mental Health,Neurology,Other Health,Other Science,Pharmaceutical,Research,Science